^
Association details:
| Biomarker: | CLDN6 positive |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug Class: | T-lymphocyte cell therapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BNT211: A phase I/IIa trial to evaluate safety and efficacy of CLDN6 CAR-T and CARVac-based in vivo expansion to improve treatment of patients with CLDN6-positive advanced solid tumors
Published date:
05/07/2021
Excerpt:
Patients with CLDN6-positive relapsed or refractory solid tumors...The underlying diseases of the first three patients were ovarian carcinoma, desmoplastic round small cell tumor and yolk sac carcinoma….The first and second tumor assessment based on RECIST 6 and 12 weeks post CLDN6 CAR-T administration indicates stable disease for patient 1.
